Nuluujaak Mountain · Photo: The Cosmonaut · CC BY-SA 2.5 ca
AbbVie to stop production of 40 mg Humira pens and syringes
AbbVie reports its Humira (adalimumab) 40 mg solution for subcutaneous injection, in pre-filled syringe and pen form, is to be discontinued on Oct 30, 2026, for business reasons.
Humira is a widely used biologic for arthritis, psoriasis and inflammatory bowel disease — patients and prescribers should confirm the switch to biosimilars or other alternatives.
